Existing Subscriber? Sign in to continue reading.

This content is free with registration! Start a free trial today! Register to keep reading and receive our free email digests

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

'Combination Product Agreement Meetings' Coming Soon From US FDA

23 Oct 2018
Analysis

Derrick Gingery @dgingery derrick.gingery@informa.com

Executive Summary

The meetings are tied to requirements from the 2016 21st Century Cures legislation. They could offer more development certainty for sponsors by allowing informal agreements with the agency on pre- and post-market issues.

Existing Subscriber? Sign in to continue reading.

This content is free with registration! Start a free trial today! Register to keep reading and receive our free email digests

Table
View full table

Topics

United States

Industries
Medical Device

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Combination Products Research and Development Strategies Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT123467

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT123467

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

'Combination Product Agreement Meetings' Coming Soon From US FDA

Analysis

Executive Summary

Related Content

FDA Approving Complex Generics Pre-ANDA Meeting Requests At Higher Rates

Combo-Product Sponsors Could More Easily Get Device Designation At US FDA

Pre-ANDA Meetings Proving Tough To Get – Nearly Half Of Requests Denied

Combo Product Review Pilot At US FDA Will Offer All Applications Intercenter Consults

US FDA Special Protocol Assessment Draft Guidance Adds Biosimilars But Not Much Clarity

FDA’s Special Protocol Rescissions Get U.S. Capitol, Venture Capital Attention

For Combination Product Development, Industry Says Talk Is Cheap

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert